Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
Early detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I−II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in ser...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/5/596 |
| _version_ | 1797715017871654912 |
|---|---|
| author | Jing Guo Wei-Lei Yang Daewoo Pak Joseph Celestino Karen H. Lu Jing Ning Anna E. Lokshin Zhongping Cheng Zhen Lu Robert C. Bast |
| author_facet | Jing Guo Wei-Lei Yang Daewoo Pak Joseph Celestino Karen H. Lu Jing Ning Anna E. Lokshin Zhongping Cheng Zhen Lu Robert C. Bast |
| author_sort | Jing Guo |
| collection | DOAJ |
| description | Early detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I−II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in sera from 76 patients with early stage (I−II), 44 patients with late stage (III−IV) ovarian cancer and 200 healthy participants in the normal risk ovarian cancer screening study. A four-biomarker panel (CA125, osteopontin (OPN), macrophage inhibitory factor (MIF), and anti-IL-8 autoantibodies) detected 82% of early stage cancers compared to 65% with CA125 alone. In early stage subjects the area under the receiver operating characteristic curve (AUC) for the panel (0.985) was significantly greater (<i>p</i> < 0.001) than the AUC for CA125 alone (0.885). Assaying an independent validation set of sera from 71 early stage ovarian cancer patients, 45 late stage patients and 131 healthy women, AUC in early stage disease was improved from 0.947 with CA125 alone to 0.974 with the four-biomarker panel (<i>p</i> = 0.015). Consequently, OPN, MIF and IL-8 autoantibodies can be used in combination with CA125 to distinguish ovarian cancer patients from healthy controls with high sensitivity. Osteopontin appears to be a robust biomarker that deserves further evaluation in combination with CA125. |
| first_indexed | 2024-03-12T08:00:38Z |
| format | Article |
| id | doaj.art-237a7b906ad54dae97ea5bdc488acf6c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T08:00:38Z |
| publishDate | 2019-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-237a7b906ad54dae97ea5bdc488acf6c2023-09-02T19:51:19ZengMDPI AGCancers2072-66942019-04-0111559610.3390/cancers11050596cancers11050596Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian CancerJing Guo0Wei-Lei Yang1Daewoo Pak2Joseph Celestino3Karen H. Lu4Jing Ning5Anna E. Lokshin6Zhongping Cheng7Zhen Lu8Robert C. Bast9Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Epidemiology, Pathology, Medicine, and Obstetrics/Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USADepartment of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USAEarly detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I−II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in sera from 76 patients with early stage (I−II), 44 patients with late stage (III−IV) ovarian cancer and 200 healthy participants in the normal risk ovarian cancer screening study. A four-biomarker panel (CA125, osteopontin (OPN), macrophage inhibitory factor (MIF), and anti-IL-8 autoantibodies) detected 82% of early stage cancers compared to 65% with CA125 alone. In early stage subjects the area under the receiver operating characteristic curve (AUC) for the panel (0.985) was significantly greater (<i>p</i> < 0.001) than the AUC for CA125 alone (0.885). Assaying an independent validation set of sera from 71 early stage ovarian cancer patients, 45 late stage patients and 131 healthy women, AUC in early stage disease was improved from 0.947 with CA125 alone to 0.974 with the four-biomarker panel (<i>p</i> = 0.015). Consequently, OPN, MIF and IL-8 autoantibodies can be used in combination with CA125 to distinguish ovarian cancer patients from healthy controls with high sensitivity. Osteopontin appears to be a robust biomarker that deserves further evaluation in combination with CA125.https://www.mdpi.com/2072-6694/11/5/596ovarian cancerosteopontin (OPN)macrophage migration inhibitory factor (MIF)CA125IL-8 autoantibodies (IL-8 AAb)early detection |
| spellingShingle | Jing Guo Wei-Lei Yang Daewoo Pak Joseph Celestino Karen H. Lu Jing Ning Anna E. Lokshin Zhongping Cheng Zhen Lu Robert C. Bast Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer Cancers ovarian cancer osteopontin (OPN) macrophage migration inhibitory factor (MIF) CA125 IL-8 autoantibodies (IL-8 AAb) early detection |
| title | Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer |
| title_full | Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer |
| title_fullStr | Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer |
| title_full_unstemmed | Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer |
| title_short | Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer |
| title_sort | osteopontin macrophage migration inhibitory factor and anti interleukin 8 autoantibodies complement ca125 for detection of early stage ovarian cancer |
| topic | ovarian cancer osteopontin (OPN) macrophage migration inhibitory factor (MIF) CA125 IL-8 autoantibodies (IL-8 AAb) early detection |
| url | https://www.mdpi.com/2072-6694/11/5/596 |
| work_keys_str_mv | AT jingguo osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT weileiyang osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT daewoopak osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT josephcelestino osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT karenhlu osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT jingning osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT annaelokshin osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT zhongpingcheng osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT zhenlu osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer AT robertcbast osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer |